KOA SHOJI HOLDINGS CO.,LTD. Logo

KOA SHOJI HOLDINGS CO.,LTD.

Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.

9273 | T

Overview

Corporate Details

ISIN(s):
JP3283420002
LEI:
Country:
Japan
Address:
横浜市港北区日吉七丁目13−15
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KOA SHOJI HOLDINGS CO., LTD. is a pharmaceutical holding group operating a dual business model that combines a trading company and a manufacturer. The group specializes in supporting the pharmaceutical industry "from upstream" by importing and distributing high-quality, safe, and reliable Active Pharmaceutical Ingredients (APIs) for the Japanese market. In addition to its core trading activities, the company also manufactures and sells generic drugs. Its integrated operations, which include contract manufacturing and packaging services, aim to provide a stable supply chain for its customers and address the healthcare needs of an aging society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 06:00
Registration Form
確認書
Japanese 8.2 KB
2025-09-29 06:00
Annual Report
有価証券報告書-第11期(2024/07/01-2025/06/30)
Japanese 1.5 MB
2025-06-20 03:20
Earnings Release
臨時報告書
Japanese 18.4 KB
2025-02-13 05:00
Interim Report
半期報告書-第11期(2024/07/01-2025/06/30)
Japanese 191.9 KB
2025-02-13 05:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-09-30 08:27
Post-Annual General Meeting Information
臨時報告書
Japanese 24.6 KB
2024-09-30 08:26
Governance Information
内部統制報告書-第10期(2023/07/01-2024/06/30)
Japanese 23.4 KB
2024-09-30 08:26
Registration Form
確認書
Japanese 8.1 KB
2024-09-30 08:25
Annual Report
有価証券報告書-第10期(2023/07/01-2024/06/30)
Japanese 1.5 MB
2024-06-26 08:25
Earnings Release
臨時報告書
Japanese 18.4 KB
2024-06-05 09:30
Registration Form
訂正有価証券届出書(参照方式)
Japanese 86.2 KB
2024-06-05 09:30
Registration Form
訂正有価証券届出書(参照方式)
Japanese 171.1 KB
2024-05-27 08:00
Registration Form
有価証券届出書(参照方式)
Japanese 101.1 KB
2024-05-27 08:00
Registration Form
有価証券届出書(参照方式)
Japanese 250.3 KB
2024-05-13 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all KOA SHOJI HOLDINGS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOA SHOJI HOLDINGS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOA SHOJI HOLDINGS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.